Pavel Anzenbacher

Prof. Pavel Anzenbacher


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Journal of Inorganic Biochemistry
Verified
Journal Article
Open access
MŠMartin Šrejber
Martin Šrejber
VNVeronika Navrátilová
Veronika Navrátilová
MPMarkéta Paloncýová
Markéta Paloncýová
VBVáclav Bazgier
Václav Bazgier
KBKarel Berka
Karel Berka
Michal OtyepkaMichal Otyepka
Michal Otyepka
Mammalian cytochromes P450 are an important class of enzymes involved in the biotransformation of many endo- and exogenous compounds. Cytochrome P450 isoforms are attached to the membrane of the endoplasmic reticulum or mitochondria, and their catalytic domains move along the membrane surface while being partially immersed in the membrane environment. Their active sites are connected to both the membrane and cytosolic environments via a complex network of access channels. Consequently, they can accept substrates from both environments. The membrane also supports the interactions of cytochromes P450 with their redox partners. In this review, we provide an overview of current knowledge of the structure, flexibility, and interactions with substrates and redox partners of cytochrome P450 on membranes, amalgamating information derived from both experiments and simulations.

1 July 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JNJana Nekvindova
Jana Nekvindova
AMAlena Mrkvicova
Alena Mrkvicova
VZVeronika Zubáňová
Veronika Zubáňová
AVAlena Hyrslova Vaculova
Alena Hyrslova Vaculova
Pavel AnzenbacherPavel Anzenbacher
Pavel Anzenbacher
VPVladimir Palicka
Vladimir Palicka

24 March 2017 in Molecules
Verified
Journal Article
Open access
PDF file
AŠAlena Špičáková
Alena Špičáková
BSBarbora Szotakova
Barbora Szotakova
DDDiana Dimunová
Diana Dimunová
Pavel AnzenbacherPavel Anzenbacher
Pavel Anzenbacher
VKVladimír Kubíček
Vladimír Kubíček
LSLenka Skalova
Lenka Skalova
Sesquiterpenes, 15-carbon compounds formed from three isoprenoid units, are the main components of plant essential oils. Sesquiterpenes occur in human food, but they are principally taken as components of many folk medicines and dietary supplements. The aim of our study was to test and compare the potential inhibitory effect of acyclic sesquiterpenes, trans-nerolidol, cis-nerolidol and farnesol, on the activities of the main xenobiotic-metabolizing enzymes in rat and human liver in vitro. Rat and human subcellular fractions, relatively specific substrates, corresponding coenzymes and HPLC, spectrophotometric or spectrofluorometric analysis of product formation were used. The results showed significant inhibition of cytochromes P450 (namely CYP1A, CYP2B and CYP3A subfamilies) activities by all tested sesquiterpenes in rat as well as in human hepatic microsomes. On the other hand, all tested sesquiterpenes did not significantly affect the activities of carbonyl-reducing enzymes and conjugation enzymes. The results indicate that acyclic sesquiterpenes might affect CYP1A, CYP2B and CYP3A mediated metabolism of concurrently administered drugs and other xenobiotics. The possible drug–sesquiterpene interactions should be verified in in vivo experiments.

13 October 2014 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
Pavel AnzenbacherPavel Anzenbacher
Pavel Anzenbacher
SMStéphane Marchal
Stéphane Marchal
JPJan Palacký
Jan Palacký
EAEva Anzenbacherová
Eva Anzenbacherová
TDThomas Domaschke
Thomas Domaschke
MMMarkéta Martínková
Markéta Martínková

1 June 2003 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
EAEva Anzenbacherová
Eva Anzenbacherová
KFKarolina Filipová
Karolina Filipová
MNMilan Nobilis
Milan Nobilis
Pavel AnzenbacherPavel Anzenbacher
Pavel Anzenbacher

21 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMartina Medvedíková
Martina Medvedíková
Václav RancVáclav Ranc
Václav Ranc
JVJan Vanco
Jan Vanco
Zdeněk TrávníčekZdeněk Trávníček
Zdeněk Trávníček
Pavel AnzenbacherPavel Anzenbacher
Pavel Anzenbacher
The effects of two anticancer active copper(II) mixed-ligand complexes of the type [Cu(qui)(mphen)]Y·H2O, where Hqui = 2-phenyl-3-hydroxy- 1H-quinolin-4-one, mphen = bathophenanthroline, and Y = NO3 (complex 1) or BF4 (complex 2) on the activities of different isoenzymes of cytochrome P450 (CYP) have been evaluated. The screening revealed significant inhibitory effects of the complexes on CYP3A4/5 (IC50 values were 2.46 and 4.88 μM), CYP2C9 (IC50 values were 16.34 and 37.25 μM), and CYP2C19 (IC50 values were 61.21 and 77.07 μM). Further, the analysis of mechanisms of action uncovered a non-competitive type of inhibition for both the studied compounds. Consequent studies of pharmacokinetic properties proved good stability of both the complexes in phosphate buffer saline (>96% stability) and human plasma (>91% stability) after 2 h of incubation. Both compounds are moderately metabolised by human liver microsomes (<30% after 1 h of incubation), and over 90% of the complexes bind to plasma proteins. The obtained results showed the potential of complexes 1 and 2 to interact with major metabolic pathways of drugs and, as a consequence of this finding, their apparent incompatibility in combination therapy with most chemotherapeutic agents.